Longevity hype meets medical reality in Silicon Valley as a flagship experiment pauses

Silicon Valley’s longevity movement gets a reality check as Bryan Johnson halted Rapamycin after years of self-testing, highlighting the gap between hype and proven science: there’s no clinical evidence that any current intervention extends human life, and much of the field rests on self-reported data and individualized tests rather than large-scale trials, even as tech culture pushes rapid experimentation and interest in aging-related drugs like metformin and GLP-1 inhibitors continues.